DMP 728 | CAS#155158-97-7 | Glycoprotein IIb-IIIa atagonist

MedKoo Cat#: 596930 | Name: DMP 728

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DMP 728 is a Glycoprotein IIb-IIIa atagonist.

Chemical Structure

DMP 728

CAS#155158-97-7

Theoretical Analysis

MedKoo Cat#: 596930

Name: DMP 728

CAS#: 155158-97-7

Chemical Formula: C26H40N8O10S

Exact Mass: 656.2588

Molecular Weight: 656.71

Elemental Analysis: C, 47.55; H, 6.14; N, 17.06; O, 24.36; S, 4.88

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

DMP 728; DMP-728; DMP728; XL 118; XL-118; XL118;

IUPAC/Chemical Name

2-((5S,11S,14R)-14-ethyl-11-(3-guanidinopropyl)-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-1(1,3)-benzenacyclohexadecaphane-5-yl)acetic acid compound with methanesulfonic acid (1:1)

InChi Key

CSRWGJAILKTYLJ-PWGAQZMISA-N

InChi Code

InChI=1S/C25H36N8O7.CH4O3S/c1-3-16-24(40)33(2)18(8-5-9-28-25(26)27)23(39)30-13-19(34)31-17(11-20(35)36)22(38)29-12-14-6-4-7-15(10-14)21(37)32-16;1-5(2,3)4/h4,6-7,10,16-18H,3,5,8-9,11-13H2,1-2H3,(H,29,38)(H,30,39)(H,31,34)(H,32,37)(H,35,36)(H4,26,27,28);1H3,(H,2,3,4)/t16-,17+,18+;/m1./s1

SMILES Code

CC[C@@H]1C(N(C)[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(NCc2cc(C(N1)=O)ccc2)=O)=O)=O)=O.CS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 656.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shi G, Lloyd TL, Sy SK, Jiao Q, Wernicki A, Mutlib A, Emm TA, Unger SE, Pieniaszek HJ Jr. Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. J Pharm Biomed Anal. 2003 Apr 1;31(5):937-51. PubMed PMID: 12684106. 2: Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. J Lab Clin Med. 2000 Mar;135(3):247-55. PubMed PMID: 10711863. 3: Rebello SS, Huang J, Faul JD, Lucchesi BR. Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists. J Thromb Thrombolysis. 2000 Jan;9(1):23-8. PubMed PMID: 10590185. 4: Huang J, Rebello SS, Faul JD, Lucchesi BR. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition. Pharmacology. 1999 May;58(5):252-64. PubMed PMID: 10087466. 5: Boxus T, Touillaux R, Dive G, Marchand-Brynaert J. Synthesis and evaluation of RGD peptidomimetics aimed at surface bioderivatization of polymer substrates. Bioorg Med Chem. 1998 Sep;6(9):1577-95. PubMed PMID: 9801829. 6: Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res. 1998 Jun 15;90(6):247-58. PubMed PMID: 9700855. 7: Hantgan RR, Mousa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res. 1998 Mar 15;89(6):271-9. PubMed PMID: 9669749. 8: Mousa SA, Bozarth JM, Edwards S, Carroll T, Barrett J. Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis. Coron Artery Dis. 1998;9(2-3):131-41. PubMed PMID: 9647415. 9: Michaelis W, Turlapaty P, Gray J, Fiske WD, Faulkner E, Kornhauser D, Mousa SA. Pharmacodynamics and pharmacokinetics of DMP 728, a platelet GPIIb/IIIa antagonist, in healthy subjects. Clin Pharmacol Ther. 1998 Mar;63(3):384-92. PubMed PMID: 9542482. 10: Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res. 1997 Oct 15;88(2):137-46. Erratum in: Thromb Res 1998 Jan 15;89(2):97. PubMed PMID: 9361367. 11: Saitoh H, Aungst BJ. Prodrug and analog approaches to improving the intestinal absorption of a cyclic peptide, GPIIb/IIIa receptor antagonist. Pharm Res. 1997 Aug;14(8):1026-9. PubMed PMID: 9279884. 12: Mousa SA, Mu DX, Lucchesi BR. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs. Stroke. 1997 Apr;28(4):830-5; discussion 835-6. PubMed PMID: 9099204. 13: Maurin MB, Rowe SM, Rockwell A, Foris CM, Hussain MA. Characterization of the salts of a cyclic RGD peptide. Pharm Res. 1996 Mar;13(3):481-4. PubMed PMID: 8692746. 14: Ribadeneira MD, Aungst BJ, Eyermann CJ, Huang SM. Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption. Pharm Res. 1996 Feb;13(2):227-33. PubMed PMID: 8932441. 15: Mousa SA, DeGrado WF, Mu DX, Kapil RP, Lucchesi BR, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Circulation. 1996 Feb 1;93(3):537-43. PubMed PMID: 8565173. 16: Dandona P, Thusu K, Khurana U, Love J, Aljada A, Mousa S. Calcium, calmodulin and protein kinase C dependence of platelet shape change. Thromb Res. 1996 Jan 15;81(2):163-75. PubMed PMID: 8822131. 17: Aungst BJ, Saitoh H. Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist. Pharm Res. 1996 Jan;13(1):114-9. PubMed PMID: 8668658. 18: Burcham DL, Aungst BA, Hussain M, Gorko MA, Quon CY, Huang SM. The effect of absorption enhancers on the oral absorption of the GP IIB/IIIA receptor antagonist, DMP 728, in rats and dogs. Pharm Res. 1995 Dec;12(12):2065-70. PubMed PMID: 8786991. 19: Reilly TM, Mousa SA, Racanelli AL, Thoolen MJ, Flint SK, Bozarth JM, Mu DX, Walton HL. A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2195-9. PubMed PMID: 7489242. 20: Maurin MB, Hussain MA. A novel isolation method of a stable crystalline salt of a cyclic RGD peptide zwitterion. Pharm Res. 1995 Nov;12(11):1810-2. PubMed PMID: 8592692.